Home » Archive

Articles Archive for Year 2019

Press Releases»

[ by | Dec 27, 2019 9:00 am | Comments Off ]
Starton Successfully Completes Proof Of Concept Study For Transdermal Lenalidomide

New York, NY (Press Release) – Starton Thera­peutics Inc. (“Starton” or the “Company”), a bio­technol­ogy com­pany focused on trans­forming standard of care thera­peutics, to­day an­nounced the com­ple­tion of a proof of concept study of multiple myeloma with lena­lido­mide using a model which emulates trans­dermal de­livery. The results of the study dem­onstrate that a con­tin­uous sub­cu­tane­ous (SC) de­livery of lena­lido­mide is superior in terms of efficacy and equivalent in tolerability when com­pared to a standard once daily pulsatile dosing of Revlimid® (Celgene Corpo­ra­tion) in mice. The pos­i­tive out­come provides a clear path …

Read the full story »

Press Releases»

[ by | Dec 27, 2019 1:00 am | Comments Off ]
Molecular Partners Receives Orphan Drug Designation For MP0250 For Multiple Myeloma

Zurich-Schlieren, Switzerland (Press Release) – Molecular Partners AG (SIX:MOLN), a clin­i­cal-stage bio­tech com­pany pioneering the use of DARPin® thera­peutics to treat serious dis­eases, announces the receipt of Orphan Drug Desig­na­tion by the US Food and Drug Admin­istra­tion (FDA) for its novel thera­peutic, MP0250, for the treat­ment of multiple myeloma.

MP0250 is a first-in-class, tri-specific multi-DARPin® drug can­di­date neutralizing VEGF-A and HGF and is binding to human serum albumin to in­crease plasma half-life. The unique mech­a­nism of action of MP0250 rep­re­sents a new ap­proach to targeting the tumor microenvironment and in­crease patients' …

Read the full story »

Holiday»

[ by | Dec 25, 2019 12:21 am | Comments Off ]
Happy Holidays!

As the 2019 holiday season reaches it peak, all of us here at The Myeloma Beacon would like to thank you, our readers and members of the myeloma com­munity world­wide, for giving us the greatest gift possible: your time.

We ap­pre­ci­ate your coming to The Beacon and reading our articles, letting us know your thoughts about them, and sharing your ex­peri­ences and helping one another.

The holiday season is a time of many dif­fer­en­t traditions. It also is a busy time, when it is easy to lose track of …

Read the full story »

Opinion»

[ by | Dec 23, 2019 3:56 pm | 8 Comments ]
Myeloma On The High Plains: My Eyes Have Been Opened

Though it has been almost five years since my initial diag­nosis, I still am somewhat un­cer­tain about what it means to live with multiple myeloma. Where does enjoying your life, LIVING your life (having fun, laughing, enjoyment, etc.) fit in with the very real and serious cir­cum­stance of multiple myeloma?

When first diag­nosed, I was sad, disappointed, un­cer­tain, and scared. It was easy to be this way be­cause I asso­ci­ated having multiple myeloma with con­stant and extreme pain, lots of suffer­ing, so much sadness, and of course my coming death. I …

Read the full story »

Press Releases»

[ by | Dec 20, 2019 9:00 am | Comments Off ]
Telo Genomics Announces Multiple Myeloma Collaboration With Mayo Clinic

Toronto, ON (Press Release) – Telo Genomics Corp. (TSX-V: TELO) (the “Com­pany” or “TELO”), is pleased to announce that it has signed a col­lab­o­ration agree­ment with Mayo Clinic in Minnesota to conduct clin­i­cal studies to eval­u­ate and val­i­date the utility of the Com­pany’s pro­pri­e­tary telomere analytics as a prog­nos­tic solu­tion for Multiple Myeloma.

The col­lab­o­ration studies will be led by Dr. Shaji Kumar, MD, and were designed to in­clude two retro­spec­tive­ phases with the poten­tial of a third pro­spec­tive­ phase. For each phase, TELO’s analytics will be employed to: 1) predict …

Read the full story »

Press Releases»

[ by | Dec 19, 2019 7:30 am | Comments Off ]
NexImmune Receives IND Clearance For Phase 1/2 Trial In Relapsed / Refractory Multiple Myeloma
  • IND clear­ance enables com­mence­ment of clin­i­cal trial to eval­u­ate NEXI-002 in multiple myeloma patients who have failed >3 pre­vi­ous lines of ther­apy
  • FDA action rep­re­sents the Com­pany’s second IND clear­ance in 4Q2019 for its pipe­line of novel cellular ther­apy prod­ucts

{{image}}Gaithersburg, MD (Press Release) – NexImmune, a clin­i­cal-stage bio­pharma­ceu­tical com­pany devel­op­ing novel immune-therapeutics based on a pro­pri­e­tary Artificial Immune Modulation (AIM) nanotechnology plat­form, has re­ceived IND clear­ance for the Com­pany’s second cellular ther­apy prod­uct. NEXI-002 is being devel­oped for the treat­ment of multiple myeloma patients that have failed at least three prior lines of ther­apy.

Scott P. Carmer, NexImmune’s Pres­i­dent and CEO, commented, “FDA clear­ance of our second IND this quarter marks another sig­nif­i­cant mile­stone for NexImmune and dem­onstrates our team’s focus and …

Read the full story »

Press Releases»

[ by | Dec 16, 2019 6:36 pm | Comments Off ]
Pivotal DREAMM-2 Study Demonstrated A Clinically Meaningful Overall Response Rate With Belantamab Mafodotin (GSK2857916) For Patients With Relapsed / Refractory Multiple Myeloma
  • Overall re­sponse­ rate (ORR) of 31% with 2.5 mg/kg regi­men and no new safety signals in heavily pre-treated patient pop­u­la­tion who were re­frac­tory to an immuno­modu­la­tory drug and a pro­te­a­some in­hib­i­tor, and were re­frac­tory or intolerant to an anti-CD38 anti­body
  • Data pub­lished in The Lancet Oncology highlight the poten­tial of be­lan­ta­mab mafo­dotin for patients with mul­ti­ple myeloma whose dis­ease has progressed
  • GSK con­firms sub­mission of a Biologics License Appli­ca­tion to the US Food and Drug Admin­istra­tion

{{image}}London, United Kingdom (Press Release) – GlaxoSmithKline plc (LSE/NYSE: GSK) today an­nounced treat­ment with the inves­ti­ga­tional single-agent be­lan­ta­mab mafo­dotin re­­sulted in a clin­i­cally meaningful 31% over­all re­sponse­ rate (ORR) with the 2.5 mg/kg regi­men in patients with heavily pre-treated mul­ti­ple myeloma. Patients in the trial re­ceived a median of seven prior lines of treat­ment, were re­frac­tory to an immuno­modu­la­tory drug and a pro­te­a­some in­hib­i­tor and were re­frac­tory and/or intolerant to an anti-CD38 anti­body. The median duration of re­sponse­ has not been reached …

Read the full story »